XCR1+ DCs can also facilitate anti-cancer immune activity in response to cancer treatments such as radiotherapy, chemotherapy and photodynamic therapy, which are all known to induce immunogenic cell death (ICD) (reviewed in [86,87,88]). This evidence concerns the gene XCR1 and cancer.